HRP940417A2 - Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof - Google Patents
Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof Download PDFInfo
- Publication number
- HRP940417A2 HRP940417A2 HRP940417A HRP940417A2 HR P940417 A2 HRP940417 A2 HR P940417A2 HR P940417 A HRP940417 A HR P940417A HR P940417 A2 HRP940417 A2 HR P940417A2
- Authority
- HR
- Croatia
- Prior art keywords
- active substance
- alprazolam
- water
- polyvinylpyrrolidone
- ethanol
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 17
- 239000007787 solid Substances 0.000 title claims description 8
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 32
- 229960004538 alprazolam Drugs 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000008021 deposition Effects 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002482 oligosaccharides Polymers 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HRP940417 HRP940417A2 (en) | 1994-07-21 | 1994-07-21 | Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HRP940417 HRP940417A2 (en) | 1994-07-21 | 1994-07-21 | Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP940417A2 true HRP940417A2 (en) | 1997-04-30 |
| HRP940417B1 HRP940417B1 (zh) | 1999-08-31 |
Family
ID=10946141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP940417 HRP940417A2 (en) | 1994-07-21 | 1994-07-21 | Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof |
Country Status (1)
| Country | Link |
|---|---|
| HR (1) | HRP940417A2 (zh) |
-
1994
- 1994-07-21 HR HRP940417 patent/HRP940417A2/hr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP940417B1 (zh) | 1999-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5405619A (en) | Controlled release therapeutic system for liquid pharmaceutical formulations | |
| EP1231903B1 (en) | Coating of tablet cores | |
| CA2390933C (en) | Oral solid preparation comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide | |
| JP2003504324A (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
| NO176203B (no) | Fremgangsmåte for fremstilling av ibuprofentabletter med forsinket frigjöring | |
| RU2669351C1 (ru) | Покрытая пленкой таблетка, содержащая холина альфосцерат, и способ ее изготовления | |
| IL141764A (en) | Controlled-release pharmaceutical formulations containing CGMP PDE-5 inhibitor | |
| JP2001501207A (ja) | コーティングされた粒子製剤 | |
| US20040081691A1 (en) | Granules containing a plant substance and process for preparing them | |
| AU616562B2 (en) | Controlled release therapeutic system for liquid pharmaceutical formulations | |
| AU2009315449B2 (en) | Novel method for preparing granulates of active principles, and granulates obtained thereof | |
| CA2363376A1 (en) | Solid pharmaceutical compositions for oral administration comprising itraconazole | |
| HRP940417A2 (en) | Solid curative forms with reliable release of alprazolame active substance and a process of the production thereof | |
| JPH0338248B2 (zh) | ||
| EP0636023B1 (en) | Aminoguanidine spray drying process | |
| KR102195162B1 (ko) | 타다라필 함유 고체분산체 및 이의 제조방법 | |
| KR100435514B1 (ko) | 실데나필 젖산염의 속효제형 | |
| RU2142791C1 (ru) | Твердая лекарственная форма, способная к стабильному выделению активного вещества альпразолама, и способ ее получения | |
| SI9300086A (sl) | Trdne zdravilne oblike z zanesljivim odpuščanjem učinkovine alprazolama in postopek za njihovo pripravo | |
| CZ289649B6 (cs) | Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy | |
| JP7391521B2 (ja) | 勃起不全治療用医薬組成物 | |
| RU2145213C1 (ru) | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения | |
| SK280799B6 (sk) | Tuhé liekové formy so spoľahlivým uvoľňovaním tera | |
| PL174889B1 (pl) | Stała postać leku w postaci dawki jednostkowej zawierającego 8-chloro-1-metylo- 6-fenylo-4H-[1,2,4]-triazolo[4,3-a] [1,4]benzodiazepinę jako substancję czynną i sposób wytwarzania tej stałej postaci leku | |
| EP0745381B1 (en) | A process for preparing pharmaceutical compositions through deposition of complexes of drugs with cyclodextrins on inert or active cores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20050603 Year of fee payment: 12 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20060722 |